

URGENT – 24 HOUR

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhccommunityplan.com for medication fax request forms.)

Patient Information

Patient's Name:

Insurance ID:

Date of Birth:

Height:

Weight:

Address:

Apartment #:

City:

State:

Zip:

Phone Number:

Alternate Phone:

Sex: ☐ Male ☐ Female

Provider Information

Provider's Name:

Provider ID Number:

Address:

City:

State:

Zip:

Suite Number:

Building Number:

Phone Number:

Fax number:

Provider's Specialty:

Medication Information

Medication:

Quantity:

ICD-10 Code:

Directions:

Diagnosis:

Refills:

Physician Signature**:

DAW (Initial here):

Physician Signature:** By signing above the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.

Medication Instructions

Has the patient been instructed on how to **Self-Administer**?

☐ Yes ☐ No

Is this medication a **New Start**?

☐ Yes ☐ No

If **NO** please provide the following:

Initiation Date: / /

Date of Last Dose: / /

****Please attach any pertinent clinical information that would pertain to support stated diagnosis.**

Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed

Delivery Instructions

Note: Delivery coordination requires a **"Physician Signature"** above and complete **"Provider Information"** and **"Patient Information"**

Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery

Ship to: Physician's Office ☐ Patient's Address ☐ Date medication is needed: / /

Medication Administered: Home Health ☐ Self Administered ☐ LTC ☐ Physician's Office ☐

4. Has the patient abstained from the use of illicit drugs and alcohol for a minimum of one month as evidence by a negative urine or blood confirmation test collected within the past 30 days prior to initiation of therapy?

Results must be submitted with this request

☐ YES ☐ NO

5. Is this patient receiving substance or alcohol abuse counseling services or seeing an addiction specialist as an adjunct to HCV treatment? ***Must submit medical records to support if YES***

☐ YES ☐ NO

6. Has the patient agreed to complete the regimen documented in medical records? ***Please submit medical record documentation if YES***

☐ YES ☐ NO

7. Has the patient verbally or in writing committed to the documented planned course of treatment including anticipated blood tests and visits, during and after treatment? ***Please submit medical record documentation if YES***

☐ YES ☐ NO

8. If the patient is a female, does the patient have documentation of a negative pregnancy test collected within 30 days prior to initiation of therapy OR medical records documenting pregnancy status as negative?

☐ YES ☐ NO

9. Does this patient have co-infection with HIV-1? ☐ YES ☐ NO

a. If yes, is this patient taking antiretroviral therapy? ☐ YES ☐ NO

b. What is this patient's CD4 count? _____ Date collected: _____

10. Does this patient have stage 3 or stage 4 hepatic fibrosis? ☐ YES ☐ NO

If yes, must submit medical record evidence to support

11. Does the patient have a decompensated liver disease defined as Child-Pugh score greater than 6 (Class B or C)? ☐ YES ☐ NO

12. Is this patient ineligible for treatment with peginterferon alfa? ☐ YES ☐ NO
If yes, please provide rationale:

13. *For Re-Authorization Requests:* Has the patient demonstrated signs of high risk behavior (recurring alcoholism, IV drug abuse, etc.) or failure to complete HCV disease evaluation appointments and procedures in follow-up reviews? ☐ YES ☐ NO

14. *For Re-Authorization Requests:* Has the patient been 100% compliant to the treatment plan?
☐ YES ☐ NO

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.

Hepatitis C Medication Management Program
Treatment Documentation Requirements
(Please submit copies of all required labs along with this request)

Date that treatment was started:

Baseline HCV-RNA: Date Collected:

Please check appropriate regimen and provide copies of labs:

<input type="checkbox"/> Genotype 1		
<input type="checkbox"/> Sovaldi, Peginterferon, Ribavirin (12 weeks)	Labs required at week 4:	Date drawn:
<input type="checkbox"/> Sovaldi, Ribavirin (24 weeks)	Labs required at week 4: Labs required at week 12:	Date drawn: Date drawn:
<input type="checkbox"/> Sovaldi, Olysio (12 weeks)	Labs required at week 4:	Date drawn:
<input type="checkbox"/> Genotype 2		
<input type="checkbox"/> Sovaldi, Ribavirin (12 weeks)	Labs required at week 4:	Date drawn:
<input type="checkbox"/> Sovaldi, Ribavirin (16 weeks – decompensated patients)	Labs required at week 4: Labs required at week 12:	Date drawn: Date drawn:
<input type="checkbox"/> Genotype 3		
<input type="checkbox"/> Sovaldi, Ribavirin (24 weeks)	Labs required at week 4: Labs required at week 12:	Date drawn: Date drawn:
<input type="checkbox"/> Genotype 4		
<input type="checkbox"/> Sovaldi, Peginterferon, Ribavirin (12 weeks)	Labs required at week 4:	Date drawn:
<input type="checkbox"/> Sovaldi, Ribavirin (24 weeks)	Labs required at week 4: Labs required at week 12:	Date drawn: Date drawn:
<input type="checkbox"/> Hepatocellular Carcinoma		
<input type="checkbox"/> Sovaldi, Ribavirin (48 weeks)	Labs required at week 4: Labs required at week 12: Labs required at week 24:	Date drawn: Date drawn: Date drawn:

Prescriber's Signature: _____ Date: _____

REQUIRED FOR REVIEW: Copies of medical records (i.e., diagnostic evaluations and recent chart notes), a copy of the original prescription, and the most recent copies of related labs.

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.